During his long career as a pediatric oncologist and cancer researcher, William Woods thought highly of the FDA's work evaluating and approving new cancer drugs. But his opinion of the agency changed when he was diagnosed with amyotrophic lateral sclerosis, or ALS, a progressive disease that damages nerves in the brain and spinal cord. This week on the "First Opinion Podcast," Woods talks about living with ALS, and watching what he sees as the glacial pace of approving an experimental ALS drug called AMX0035.